Investigating subtle kidney injury in primary hyperparathyroidism by means of sensitive and specific biomarkers.
Aged
Biomarkers
/ blood
Calcium
/ blood
Creatinine
/ blood
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Female
Fibroblast Growth Factor-23
Fibroblast Growth Factors
/ blood
Glomerular Filtration Rate
/ physiology
Glucuronidase
/ blood
Hepatitis A Virus Cellular Receptor 1
/ metabolism
Humans
Hyperparathyroidism, Primary
/ blood
Kidney
/ injuries
Kidney Diseases
/ blood
Klotho Proteins
Male
Middle Aged
Phosphorus
/ blood
Postmenopause
/ blood
chronic kidney disease
injury
kidney
primary hyperparathyroidism
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
17
04
2019
revised:
24
06
2019
accepted:
12
07
2019
pubmed:
17
7
2019
medline:
9
9
2020
entrez:
17
7
2019
Statut:
ppublish
Résumé
Kidney involvement is a common complication in primary hyperparathyroidism (PHPT). No study so far has assessed the prevalence of kidney injury developing before the reduction in glomerular filtration rate (GFR) in PHPT. The study was aimed at establishing the potential role of biomarkers of kidney injury in detecting subtle renal damage in patients with PHPT. Cross-sectional study. A total of 69 postmenopausal patients with PHPT and 41 healthy age- and sex-matched subjects were studied. Exclusion criteria were as follows: GFR < 30 mL/min, chronic inflammatory disease, nephrotic syndrome, infection, malignancy, heart failure, recent exposure to iodinated contrast media or nonsteroidal anti-inflammatory drugs. We measured a panel of sensitive biomarkers of kidney injury in PHPT vs controls. Mean FGF23 and Klotho were higher in PHPT (72 ± 48 and 811 ± 366 pg/mL, respectively) than controls (53 ± 23.5 and 668.6 ± 17; P < .02 and P < .05). Urine KIM-1/uCr was significantly higher in PHPT (1.4 We propose the utilization of these molecules, particularly urine KIM-1/uCr and urine NGAL/uCr ratios for the assessment of subtle kidney injury in patients with PHPT. These molecules are elevated in tubular necrosis and have potential role in the development of kidney damage in PHPT, according to the severity of the disease.
Substances chimiques
Biomarkers
0
FGF23 protein, human
0
HAVCR1 protein, human
0
Hepatitis A Virus Cellular Receptor 1
0
Phosphorus
27YLU75U4W
Fibroblast Growth Factors
62031-54-3
Fibroblast Growth Factor-23
7Q7P4S7RRE
Creatinine
AYI8EX34EU
Glucuronidase
EC 3.2.1.31
Klotho Proteins
EC 3.2.1.31
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
660-668Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168-178.
Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723.
Silverberg S, Liu J, Marcocci C, Walker MD. Primary hyperparathyroidism. In: Bilezikian JP,Bouillon R, Clemens T, et al. eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 9th ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2019:619-628.
Cipriani C, Biamonte F, Costa AG, et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab. 2015;100(4):1309-1315.
Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-3569.
Verdelli C, Corbetta S. Mechanisms in endocrinology: kidney involvement in patients with primary hyperparathyroidism: an update on clinical and molecular aspects. Eur J Endocrinol. 2017;176(1):R39-R52.
Ejlsmark-Svensson H, Bislev LS, Rolighed L, Sikjaer T, Rejnmark L. Predictors of renal function and calcifications in primary hyperparathyroidism: a nested case-control study. J Clin Endocrinol Metab. 2018;103(9):3574-3583.
Walker MD, Nickolas T, Kepley A, et al. Predictors of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(5):1885-1892.
Ermetici F, Filopanti M, Verga U, et al. Estimated glomerular filtration rate by serum cystatin C correlates with cardiometabolic parameters in patients with primary hyperparathyroidism. Eur J Endocrinol. 2015;173(4):441-446.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012, clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 20123:1-150.
Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756-766.
Cipriani C, Pepe J, Clementelli C, et al. Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. Br J Clin Pharmacol. 2017;83:2266-2273.
Griffin BR, Gist KM, Faubel S. Current status of novel biomarkers for the diagnosis of acute kidney injury: a historical perspective. J Intensive Care Med. 2019;885066618824531. https://doi.org/10.1177/0885066618824531
Griffin BR, Faubel S, Edelstein CL. Biomarkers of drug-induced kidney toxicity. Ther Drug Monit. 2019;41(2):213-226.
Nozaki Y, Kinoshita K, Yano T, et al. Estimation of kidney injury molecule-1 (Kim-1) in patients with lupus nephritis. Lupus. 2014;23(8):769-777.
Siddiqui K, Al-Malki B, George TP, Nawaz SS, Rubeaan KA. Urinary N-acetyl-beta-d-glucosaminidase (NAG) with neutrophil gelatinase-associated lipocalin (NGAL) improves the diagnostic value for proximal tubule damage in diabetic kidney disease 3 Biotech. 2019;9:66. https://doi.org/10.1007/s13205-019-1593-z
Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2(7929):309-310.
Cipriani C, Romagnoli E, Pepe J, et al. Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. J Clin Endocrinol Metab. 2013;98(7):2709-2715.
Moresco RN, Bochi GV, Stein CS, De Carvalho J, Cembranel BM, Bollick YS. Urinary kidney injury molecule-1 in renal disease. Clin Chim Acta. 2018;487:15-21.
Lichosik M, Jung A, Jobs K, Mierzejewska A, Zdanowski R, Kalicki B. Interleukin 18 and neutrophil-gelatinase associated lipocalin in assessment of the risk of contrast-induced nephropathy in children. Cent Eur J Immunol. 2015;40(4):447-453.
Yi B, Hu X, Zhang H, et al. Nuclear NF-kappaB p65 in peripheral blood mononuclear cells correlates with urinary MCP-1, RANTES and the severity of type 2 diabetic nephropathy. PLoS ONE. 2014;9(6):e99633.
Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010;78(12):1252-1262.
Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73(2):213-224.
Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-326.
Hu MC, Kuro-o M, Moe OW. Klotho and kidney disease. J Nephrol. 2010;23(Suppl. 16):S136-S144.
Christov M. Fibroblast growth factor 23 in acute kidney injury. Curr Opin Nephrol Hypertens. 2014;23(4):340-345.
Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237-244.
Yin C, Wang N. Kidney injury molecule-1 in kidney disease. Ren Fail. 2016;38(10):1567-1573.
Panduru NM, Sandholm N, Forsblom C, et al. Kidney injury molecule-1 and the loss of kidney function in diabetic nephropathy: a likely causal link in patients with type 1 diabetes. Diabetes Care. 2015;38(6):1130-1137.
Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol. 2017;177(6):R297-R308.
Rysz J, Gluba-Brzozka A, Franczyk B, Jablonowski Z, Cialkowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int J Mol Sci. 2017;18:E1702: 1-17 .
Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Investig. 2005;115(3):610-621.
Urbschat A, Gauer S, Paulus P, et al. Serum and urinary NGAL but not KIM-1 raises in human postrenal AKI. Eur J Clin Invest. 2014;44(7):652-659.
Qian S, Huang Y, Wang N, Ding Y, Qi J, Yu Y. Urinary neutrophil gelatinase-associated lipocalin as a biomarker to monitor renal function in patients with obstructive ureteral calculi. World J Urol. 2018;37:1197-1204.
Witteveen JE, van Lierop AH, Papapoulos SE, Hamdy NA. Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism? Eur J Endocrinol. 2012;166(1):55-60.
Minisola F, Cipriani C, Colangelo L, et al. Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study. Endocrine. 2018;59(2):338-343.
Andrukhova O, Bayer J, Schüler C, et al. Klotho lacks an FGF23-independent role in mineral homeostasis. J Bone Miner Res. 2017;32(10):2049-2061.
Nilsson IL, Norenstedt S, Granath F, Zedenius J, Pernow Y, Larsson TE. FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery. 2016;159(1):211-217.